Abbott Receives CE Mark for Amulet 360 Device to Reduce Stroke Risk

Key Facts

In a move that strengthens the company's position in the advanced medical device sector, Abbott announced that its Amulet 360 device has received the European CE Mark. This next-generation device is intended to treat atrial fibrillation patients at risk of stroke by occluding the left atrial appendage (LAA). This regulatory approval officially allows the device's use across European markets, marking an expansion of the company's cardiac care portfolio.

The Amulet 360 design builds upon technical improvements aimed at achieving better sealing and safety compared to first-generation designs, supporting continued growth in the healthcare segment. According to reports, the device is engineered to reduce stroke risk in patients with non-valvular atrial fibrillation. This approval represents the company's fourth major electrophysiology regulatory milestone in just over a year, reflecting the pace of innovation in its product pipeline.

Operationally, this development comes as market data shows stability in Services PMI across major economies, such as the Eurozone which recorded 51.7 on August 21, 2026. With current price data for ABT shares unavailable at this time, investors will monitor how this European certification impacts the company's medical device market share, especially as markets await new global economic data in the coming days.